Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1994-12-7
|
| pubmed:abstractText |
The Navajo are known to be at high risk for hepatitis A virus (HAV) infection. This study investigated the safety and immunogenicity of an investigational, alum-adjuvanted, formalin-inactivated HAV vaccine (VAQTA) developed by Merck Research Laboratories in Navajo children. One hundred two of 212 children, ages 4 to 12 years, were HAV-seronegative (< 10 mIU/ml by an enhanced sensitivity modification of the HAVAB; Abbott). Ninety of these children received the HAV vaccine. Study participants were given vaccines containing various viral protein concentrations: Group A (n = 18), 6 units; Group B (n = 36), 13 units; and Group C (n = 36), 25 units HAV protein (1 unit approximately 1 ng viral protein antigen). Three-dose (0, 8, 24 weeks) and two-dose (0, 24 weeks) regimens were compared in subgroups within B and C. The vaccine was well-tolerated and there were no serious adverse reactions; no vaccinee developed hepatitis A. After 1 dose 82 to 100% of children seroconverted (> or = 10 mIU/ml, modified HAVAB; Abbott) and 100% seroconverted after 2 doses. After 1 dose the geometric mean titer for antibody was: Group A, 22 mIU/ml; Group B, 18 mIU/ml; and Group C, 38 mIU/ml. After 3 doses geometric mean titers increased to 10,106 mIU/ml in Group A, 7258 mIU/ml in Group B and 11,856 mIU/ml in Group C. Further field studies are indicated to evaluate its use in high risk populations, such as the Navajo.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0891-3668
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
640-2
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7970954-Age Factors,
pubmed-meshheading:7970954-Child,
pubmed-meshheading:7970954-Child, Preschool,
pubmed-meshheading:7970954-Dose-Response Relationship, Immunologic,
pubmed-meshheading:7970954-Female,
pubmed-meshheading:7970954-Hepatitis A,
pubmed-meshheading:7970954-Hepatitis A Vaccines,
pubmed-meshheading:7970954-Hepatitis A Virus, Human,
pubmed-meshheading:7970954-Hepatitis Antibodies,
pubmed-meshheading:7970954-Humans,
pubmed-meshheading:7970954-Immunization Schedule,
pubmed-meshheading:7970954-Immunogenetics,
pubmed-meshheading:7970954-Indians, North American,
pubmed-meshheading:7970954-Male,
pubmed-meshheading:7970954-Regression Analysis,
pubmed-meshheading:7970954-Seroepidemiologic Studies,
pubmed-meshheading:7970954-Vaccination,
pubmed-meshheading:7970954-Vaccines, Inactivated,
pubmed-meshheading:7970954-Viral Hepatitis Vaccines
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children.
|
| pubmed:affiliation |
Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|